Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune Mechanisms and Translational Study Design in Viral Vaccine Development.

International journal of molecular sciences·2026
Same author

Modification of pre-operative order set to reduce PACU stay times for outpatient benign gynecological surgery.

PloS one·2026
Same author

Tracking spatio-temporal dynamics of early immune responses to an intranasal OMV-based pneumococcal vaccine candidate in mice.

NPJ vaccines·2026
Same author

Evaluation of an Empowerment Self-Defense Program Among Middle School Youth on a Rural Reservation.

Health education & behavior : the official publication of the Society for Public Health Education·2026
Same author

Targeted Lymph Node Immunization with Serotype-Specific Dengue VLP Vaccines Enhances Antibody Avidity and Specificity.

Vaccines·2025
Same author

Discovery of Pyrazole-3-Carboxylic Acid Derivatives as Dengue Virus Protease Inhibitors with Antiviral Activity.

ACS medicinal chemistry letters·2025

Related Experiment Video

Updated: Jun 28, 2026

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

Intranasal influenza vaccination using an outer membrane vesicle platform.

Ann-Christin Magnusson1, Stephanie Lim2, Calle Niemi1

  • 1Abera Bioscience AB, Uppsala, Sweden.

Vaccine
|June 26, 2026
PubMed
Summary

A novel intranasal influenza A vaccine using outer membrane vesicles (OMVs) effectively induced mucosal immunity and protected mice against influenza virus challenge, offering a promising alternative to traditional egg-based vaccines.

Keywords:
HemagglutininMucosalOMVVaccine

More Related Videos

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

Related Experiment Videos

Last Updated: Jun 28, 2026

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

Area of Science:

  • Vaccinology
  • Immunology
  • Biotechnology

Background:

  • Traditional egg-based influenza vaccines have limitations including long production times and difficulty matching circulating strains.
  • Current intramuscular vaccines primarily induce systemic immunity, with limited mucosal immune responses crucial for respiratory pathogens.
  • Mucosal vaccination strategies are being explored to enhance protection against airborne infections like influenza.

Purpose of the Study:

  • To develop and evaluate an intranasal influenza A vaccine candidate utilizing an outer membrane vesicle (OMV) platform.
  • To assess the immunogenicity and protective efficacy of the OMV-based intranasal vaccine in a mouse model.

Main Methods:

  • Outer membrane vesicles (OMVs) were engineered for high-density covalent decoration with recombinant influenza A hemagglutinin (HA) antigen.
  • The OMV-HA vaccine candidate was administered intranasally to mice three times over a two-week interval.
  • Immune responses (IgG, IgA) and protection against influenza virus challenge were measured post-vaccination.

Main Results:

  • Intranasal vaccination with the OMV-HA candidate induced antigen-specific IgG after two doses.
  • A significant induction of IgA was observed in nasal lavage fluid and lung tissue, indicating strong mucosal immunity.
  • Vaccinated mice showed no detectable influenza virus in nasal or lung tissues post-challenge and were protected from clinical signs of disease.

Conclusions:

  • The intranasal OMV influenza vaccine candidate successfully elicits a robust mucosal immune response.
  • This OMV-based vaccine demonstrates significant protective efficacy against influenza A virus challenge.
  • The OMV platform offers a promising approach for developing next-generation intranasal influenza vaccines.